Get the Stockscreener App
7.13
0.00%
0.00
After Hours:
7.12
-0.010
-0.14%
G 1 Therapeutics Inc stock is traded at $7.13, with a volume of 2.58M.
It is up +0.00% in the last 24 hours and up +67.76% over the past month.
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
See More
Previous Close:
$7.13
Open:
$7.13
24h Volume:
2.58M
Relative Volume:
1.28
Market Cap:
$376.17M
Revenue:
$58.20M
Net Income/Loss:
$-44.77M
P/E Ratio:
-4.2189
EPS:
-1.69
Net Cash Flow:
$-37.54M
1W Performance:
+0.28%
1M Performance:
+67.76%
6M Performance:
+101.98%
1Y Performance:
+326.95%
1-Day Range:
$7.12
$7.13
1-Week Range:
$7.09
$7.13
52-Week Range:
$1.08
$7.19
G 1 Therapeutics Inc Stock (GTHX) Company Profile
Name
G 1 Therapeutics Inc
Sector
Industry
Phone
919-213-9835
Address
700 PARK OFFICES DRIVE, RESEARCH TRIANGLE PARK, NC
G 1 Therapeutics Inc Stock (GTHX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-03-23 | Reiterated | Needham | Buy |
| Nov-04-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Sep-30-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-17-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-26-20 | Initiated | ROTH Capital | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-08-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-07-19 | Initiated | B. Riley FBR | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-20-18 | Initiated | Raymond James | Strong Buy |
| Nov-08-18 | Reiterated | Needham | Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-29-18 | Initiated | H.C. Wainwright | Buy |
| May-18-18 | Reiterated | Needham | Buy |
View All
G 1 Therapeutics Inc Stock (GTHX) Latest News
Pharmacosmos moves forward with G1 Therapeutics buyout - Investing.com India
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - StockTitan
Keeping an Eye on G1 Therapeutics Inc (GTHX) After Insider Trading Activity - Knox Daily
Panagora Asset Management Inc. Buys New Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
A company insider recently sold 1,337 shares of G1 Therapeutics Inc [GTHX]. Should You Sale? - Knox Daily
The Significance of Moving Averages in G1 Therapeutics Inc Inc. (GTHX) Price Performance - The InvestChronicle
G1 Therapeutics Inc (GTHX) gets rating Upgrade from JP Morgan - Knox Daily
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.12, a 0.28 Surge/Decline - The Dwinnex
It is Poised to be a Bull Market for G1 Therapeutics Inc (GTHX) - SETE News
G1 Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
It would be worthwhile to take a closer look at G1 Therapeutics Inc (GTHX) - US Post News
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.09, a -0.28 Surge/Decline - The Dwinnex
The Potential Rise in the Price of G1 Therapeutics Inc (GTHX) following insiders activity - Knox Daily
A look into G1 Therapeutics Inc (GTHX)’s deeper side - SETE News
G1 Therapeutics, Inc. (NASDAQ:GTHX) Position Raised by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Raises Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX) - Defense World
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP) - GlobeNewswire Inc.
Pharmacosmos ventures into oncology and merges with G1 Therapeutics - MSN
TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel - CGTLive™
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates - MSN
G1 Therapeutics surges on merger deal with Pharmacosmos - MSN
Pharmacosmos Group’s Acquisition of G1 Therapeutics - Global Legal Chronicle
Q3 2024 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Raised by Analyst - Defense World
Q3 2024 EPS Estimates for G1 Therapeutics, Inc. Lifted by Analyst (NASDAQ:GTHX) - MarketBeat
G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Earn Q3 2025 Earnings of ($0.04) Per Share - Defense World
G1 Therapeutics (NASDAQ:GTHX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS - Defense World
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc.GTHX - Business Wire
Wedbush Equities Analysts Cut Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by Needham & Company LLC - Defense World
HC Wainwright Lowers G1 Therapeutics (NASDAQ:GTHX) to Hold - Defense World
FY2027 Earnings Estimate for G1 Therapeutics, Inc. (NASDAQ:GTHX) Issued By Wedbush - Defense World
G1 Therapeutics (GTHX) Shares Surge Following Acquisition Announcement - The Fosters Leader
Pharmacosmos ventures into oncology and merges with G1 Therapeutics - Pharmaceutical Technology
G1 Therapeutics (NASDAQ:GTHX) Lowered to Hold at Wedbush - MarketBeat
Wall Street Analyst Upgrade G1 Therapeutics Inc [GTHX]. What else is Wall St. saying - The DBT News
FY2027 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Boosted by Wedbush - MarketBeat
G1 Therapeutics (NASDAQ:GTHX) Downgraded by Wedbush - Defense World
G1 Therapeutics Inc (GTHX) Q2 2024 Earnings: EPS of $(0.10) Beat - GuruFocus.com
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - ForexTV.com
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - StockTitan
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders - The Malaysian Reserve
G1 Therapeutics Sees Unusually Large Options Volume (NASDAQ:GTHX) - Defense World
Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos - MedCity News
3 Firms Steer $405M G1-Pharmacosmos Pharma Deal - Law360
Pharmacosmos Group to acquire G1 Therapeutics for $7.15 per share - TipRanks
Investors Purchase High Volume of Call Options on G1 Therapeutics (NASDAQ:GTHX) - MarketBeat
Crude Oil Jumps Over 3%; Upstart Shares Spike Higher - Benzinga
G 1 Therapeutics Inc Stock (GTHX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):